Terns's stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharmaceuticals Inc.’s stock was soaring 14% Wednesday, as analysts cheered positive data released a day earlier on a treatment for chronic myeloid leukemia.The data from an early-stage trial of TERN-701 were very encouraging, according to Mizuho analysts Graig Suvannavejh and Avantika Joshi. ...